Regencell Bioscience Holdings (NASDAQ: RGC) experienced an extraordinary stock price increase exceeding 64,000% during a speculative frenzy in mid-2025. The Hong Kong-based biotech focuses on Traditional Chinese Medicine formulations targeting neurocognitive disorders such as ADHD and autism but has yet to commercialize products. A 38-for-1 stock split and social media hype fueled the volatile rally, followed by a sharp price plunge. The episode illustrates the risks associated with meme-driven biotech valuations.